spacer
home > ebr > spring 2002 > building value through biotechnology partnering
PUBLICATIONS
European Biopharmaceutical Review

Building Value Through Biotechnology Partnering

It is critical for early stage biotechnology companies to build long-term sustainable value. 'Early stage' is intended to include any company - public or private - without recurring revenue from product sales, so the vast majority of biotech companies are included in this definition. Everyone seeks high value partnerships with major pharmaceutical companies, but either companies partner early, giving away a very significant portion of their long-term value, or they fail to build the full range of capabilities in a timely manner to enable the underlying value of their technology to be realised. In addition, pharma-biotech collaborations are challenging to manage, not least because of the significant cultural differences between the two types of organisation. Collaborations between biotechs offer a means of rapidly building value, but often these biotech-biotech deals fail to deliver. In this article, pharma-biotech and biotech-biotech collaborations are analysed, common reasons for failure are identified, and some models for successful biotech-biotech collaborations are discussed.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Mike Grey, Chief Business Officer at Structural GenomiX, Inc.

Mike Grey is Executive Vice President, Chief Business Officer and a Director of Structural GenomiX, Inc. - a San Diego-based drug discovery company utilising a genomics-driven, high throughput platform that enables the determination of the 3-D structures of large numbers of proteins and protein/compound co-crystals very rapidly.
A chemist by training, Mike has held senior positions in a number of North American Biotechnology companies, including President and Chief Executive Officer of Trega Biosciences, Inc. and President of BioChem Therapeutic, Inc., the pharmaceutical operating division of BioChem Pharma Inc. From 1974 to 1993, he served in various roles with Glaxo Inc. and Glaxo Holdings, p.l.c., culminating in his position as Vice President, Corporate Development and Director, International Licensing. Mike also serves on the board of several US biotechnology companies.

spacer
Mike Grey
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sartorius debuts the Intellicyt iQue3 at CYTO® 2019

Sartorius will be showcasing the latest addition to its cellular analysis portfolio on booth #103 at this year’s CYTO® conference and exhibition, with the launch of the Intellicyt iQue3. The event – which takes place in Vancouver, Canada, from June 22 to 26 – will give delegates the chance to explore a smarter way to perform flow cytometry experiments.
More info >>

White Papers

Igb Tamper Evident Folding Box

IGB

The easiest, safest and less expensive solution in compliance with what requires Dir. 62/2011/EU, FDA and TGA.
More info >>

 
Industry Events

ELRIG Drug Discovery 2019 – Looking Back to the Future

5-6 November 2019, ACC, Liverpool

Now in its 13th year, ELRIG’s flagship conference Drug Discovery 2019 will take place at ACC in Liverpool. This year’s focus, ‘A Look Back to the Future’ is planned to include plenary introductions assessing how we got to where we are now and setting the challenges for discovering the drugs of the future. These will be followed by cutting edge talks and examples of new directions in drug discovery. Our scientific programme will feature over 40 world-class speakers with 6 main session tracks. In partnership with key academic and charitable groups, we will also run joint disease and biology-oriented tracks focusing on the basic sciences that underpin successful drug discovery.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement